Xilio Therapeutics (XLO) Return on Equity (2021 - 2026)

Xilio Therapeutics has disclosed Return on Equity across 6 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 3.0% YoY), and the FY2025 annual result was 0.02%, up 1.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Xilio Therapeutics, up from 0.03% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.85% in Q3 2025 to a low of 0.06% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2023), against an average of 0.03%.
• Peak annual rise in Return on Equity reached 88 bps in 2025, while the deepest fall reached 4 bps in 2025.
• Xilio Therapeutics' Return on Equity stood at 0.01% in 2022, then tumbled by 130 bps to 0.02% in 2023, then tumbled by 77 bps to 0.03% in 2024, then increased by 2 bps to 0.03% in 2025, then soared by 75 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.03% (Q4 2025), and 0.85% (Q3 2025), per Business Quant data.